News | Heart Valve Technology | September 17, 2018

4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018

Early adopters will share attributes, implant procedure experience with transcatheter mitral valve replacement (TMVR) device

4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018

September 17, 2018 — 4C Medical Technologies Inc. announced that its AltaValve transcatheter mitral valve replacement (TMVR) technology will be highlighted at the Transcatheter Cardiovascular Therapeutics (TCT) meeting, Sept. 21-25, 2018 in San Diego. The technology will be highlighted in the following presentations:

  • Friday, Sept. 21, 2018 at 3:45 p.m. during Innovation Sessions:
    • "4C Medical's AltaValve: The First Human Experience" by Josep Rodés-Cabau, M.D.;
  • Sunday, Sept. 23, 2018 at 3:50 p.m. during Edited Taped Cases:
    • "AltaValve TMVR" presented by Rodés-Cabau; and
  • Monday, Sept. 24, 2018 at 10:12 a.m. during Didactic Session: Transcatheter Mitral Valve Therapies, Part 2 - TMVR:
    • "AltaValve: Device Attributes, Implant Procedure, and First-in-Human" presented by Philippe Généreux, M.D.

Rodés-Cabau is the director of catheterization and interventional laboratories in Quebec Heart and Lung Institute, associate professor of medicine of Laval University and Canadian Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions (Quebec City, Quebec, Canada).

Généreux is co-director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, N.J.) and a practicing Interventional cardiologist at Hôpital du Sacré-Coeur de Montréal (Montreal, Canada).

In contrast with other TMVR devices, the AltaValve is the first mitral regurgitation (MR) treatment device that is placed in the left atrium, thus preserving the left ventricle. Furthermore, due to supra-annular positioning of the valve, AltaValve avoids issues related to the complexity and dynamics of the mitral annulus, making it suitable for patients independent of their MR mechanism.

The AltaValve is a self-expanding device that may be inserted into the left atrium using either a transseptal or a transapical delivery system.

For more information: www.4cmed.com

 

Related Content

Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Providing Follow-Up Care After Heart Attack Helps Reduce Readmissions, Deaths
News | Cath Lab | April 09, 2019
A program designed to help heart attack patients with the transition from hospital to outpatient care can reduce...
TherOx Receives FDA Approval for SuperSaturated Oxygen Therapy
Technology | Cath Lab | April 08, 2019
TherOx Inc. announced that the U.S. Food and Drug Administration (FDA) granted premarket approval for its...
Cook Medical Recalls Transseptal Needle Due to Risk of Detached Plastic Fragments
News | Cath Lab | March 20, 2019
March 20, 2019 — Cook Medical is recalling one lot of its...
DABRA Excimer Laser System Demonstrates Success in Treating PAD
News | Cath Lab | February 27, 2019
Ra Medical Systems Inc. announced a 98 percent success rate in the results from a 52-patient study using the company’s...
Edwards Lifesciences Recalls Swan-Ganz hemodynamic catheters.
Feature | Cath Lab | February 06, 2019
Edwards Lifesciences is recalling its 131F7, 131F7J, 131F7P, 131VF7P, 151F7 Swan-Ganz Thermodilution Catheters manufa
Overlay Init